Healthcare stocks are experiencing a sell-off amid ongoing turbulence in the Middle East. As of late October 2023, the sector is grappling with multiple challenges, including recent Medicaid cuts, pharmaceutical tariffs, and changes to Medicare’s Part D prescription-drug coverage. Despite a 25% return spike through February, the volatility has led to renewed concerns.
Notable companies in focus include Pfizer (PFE), which is facing a critical “patent cliff” impacting $17 billion of its annual revenue. The company is working to pivot towards new revenue streams, notably in GLP-1 weight-loss drugs, following a significant drop in stock value since late 2021. Additionally, Alexandria Real Estate Equities (ARE) reported a 75% decline post-2022 and plans to reduce its property count and capital expenditures amid rising interest rates and an oversupplied market.
Key dividend yields highlighted range from 6.0% for Alexandria to an impressive 14.1% for abrdn Healthcare Investors (HQH), which focuses on a diverse biotechnology portfolio. With market pressures intensifying, healthcare investors are assessing whether the high yields of these stocks are sustainable amidst the turbulent landscape.
